ABMT logo

Advanced Biomedical Technologies, Inc. (ABMT) Análisis de Acciones

Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Cotizando a $, Advanced Biomedical Technologies, Inc. (ABMT) es una empresa del sector Healthcare valorada en 0. La acción obtiene una puntuación de 68/100, una calificación moderada basada en 9 KPI cuantitativos.

Ultimo analisis: 16 mar 2026
Puntuación de IA de 68/100

Advanced Biomedical Technologies, Inc. (ABMT) Resumen de Asistencia Médica y Tuberías

CEOHui Wang
Empleados17
Sede CentralNew York City, US
Año de la oferta pública inicial (OPI)2010

Advanced Biomedical Technologies, Inc. is a development stage company specializing in biomaterial internal fixation devices, including surgical screws and binding wires, targeting orthopedic trauma and reconstructive dental procedures. With a negative P/E ratio and high gross margin, ABMT operates in the competitive medical device sector, facing challenges in achieving profitability and scaling production.

Procedencia de los datos | Datos financieros Análisis cuantitativo NASDAQ Análisis: 16 mar 2026

Tesis de Inversión

Advanced Biomedical Technologies, Inc. presents a high-risk, high-reward investment opportunity. The company's focus on polymer osteosynthesis devices for orthopedic and dental applications addresses a significant market need. However, as a development stage company with a negative P/E ratio of -0.05 and a negative profit margin of -190.2%, ABMT's financial viability is a major concern. Key value drivers include successful product development, regulatory approvals, and market adoption of its devices. Growth catalysts include expanding its product line and entering new geographic markets. Potential risks include competition from established medical device companies, challenges in securing funding, and the uncertainty of regulatory approvals. Investors should carefully consider the company's financial position and the inherent risks associated with development stage companies before investing. The company's high Beta of 1.46 suggests higher volatility compared to the overall market.

Basado en las finanzas de FMP y el análisis cuantitativo

Puntos clave

  • Gross Margin of 81.9% indicates strong potential profitability if sales volume increases.
  • Negative P/E Ratio of -0.05 reflects the company's current lack of profitability.
  • Profit Margin of -190.2% highlights significant operational challenges and high expenses relative to revenue.
  • Market Cap of $0.00B indicates the company is a micro-cap stock with limited liquidity.
  • Beta of 1.46 suggests the stock is more volatile than the market.

Competidores y Pares

Fortalezas

  • Proprietary biomaterial technology.
  • Focus on a specific niche market.
  • Potential for high gross margins.
  • Experienced management team.

Debilidades

  • Development stage company with limited revenue.
  • Negative profitability and cash flow.
  • Small size and limited resources.
  • Dependence on regulatory approvals.

Catalizadores

  • Upcoming: Potential FDA approval for new biomaterial internal fixation devices.
  • Ongoing: Research and development efforts to expand product line.
  • Ongoing: Strategic partnerships with hospitals and clinics to increase market reach.

Riesgos

  • Potential: Competition from established medical device companies.
  • Potential: Challenges in securing funding for ongoing operations.
  • Potential: Uncertainty of regulatory approvals.
  • Ongoing: Negative profitability and cash flow.
  • Ongoing: Limited financial disclosure due to OTC listing.

Oportunidades de crecimiento

  • Expansion into New Therapeutic Areas: ABMT can explore opportunities to expand its product offerings into adjacent therapeutic areas within orthopedics and reconstructive surgery. For example, the company could develop devices for spinal fusion or joint replacement. The global market for spinal implants is projected to reach $12.5 billion by 2028, presenting a significant growth opportunity for ABMT. Timeline: 2-3 years.
  • Geographic Expansion: ABMT can pursue geographic expansion into international markets, particularly in emerging economies where there is a growing demand for advanced medical devices. The Asia-Pacific region is expected to be the fastest-growing market for medical devices, driven by increasing healthcare spending and a growing aging population. Timeline: 3-5 years.
  • Strategic Partnerships: ABMT can form strategic partnerships with hospitals, clinics, and distributors to expand its market reach and accelerate product adoption. Collaborating with key opinion leaders and academic institutions can also help to validate the company's technology and enhance its credibility. Timeline: 1-2 years.
  • Product Innovation: ABMT can invest in research and development to develop innovative biomaterial internal fixation devices with improved performance, biocompatibility, and ease of use. The company can also explore the use of advanced manufacturing techniques, such as 3D printing, to create customized implants tailored to individual patient needs. Timeline: Ongoing.
  • Securing Regulatory Approvals: Obtaining regulatory approvals from agencies such as the FDA in the United States and the EMA in Europe is crucial for ABMT to commercialize its products and gain market access. The company should prioritize regulatory compliance and invest in the necessary resources to navigate the regulatory approval process efficiently. Timeline: Ongoing.

Oportunidades

  • Expansion into new therapeutic areas.
  • Geographic expansion into emerging markets.
  • Strategic partnerships with hospitals and distributors.
  • Increasing demand for minimally invasive surgical procedures.

Amenazas

  • Competition from larger, more established medical device companies.
  • Technological obsolescence.
  • Changes in regulatory requirements.
  • Product liability claims.

Ventajas competitivas

  • Proprietary biomaterial formulations.
  • Specialized expertise in polymer osteosynthesis.
  • Focus on niche applications in orthopedic and dental surgery.
  • Established relationships with key opinion leaders in the medical field.

Acerca de ABMT

Founded in 2002 and rebranded in 2009 from Geostar Mineral Corporation, Advanced Biomedical Technologies, Inc. (ABMT) is a development stage company focused on the design, development, manufacturing, and marketing of biomaterial internal fixation devices. The company's core offerings include polymer osteosynthesis devices such as surgical screws, binding wires, and rods, along with related medical devices. These products are intended for use in the treatment of orthopedic trauma, sports-related medical treatment, cartilage repair, reconstructive dental procedures, and related treatments. Based in New York City, ABMT aims to provide innovative solutions in the medical device field, particularly in the area of internal fixation. As a development stage company, ABMT is likely focused on research and development, clinical trials, and securing regulatory approvals for its products. The company's success will depend on its ability to effectively commercialize its products and gain market share in a competitive landscape. With a relatively small team of 17 employees, ABMT faces the challenges of scaling its operations and competing with larger, more established players in the medical device industry.

Qué hacen

  • Designs biomaterial internal fixation devices.
  • Develops polymer osteosynthesis devices.
  • Manufactures surgical screws and binding wires.
  • Markets medical devices for orthopedic trauma.
  • Offers solutions for sports-related medical treatment.
  • Provides devices for cartilage repair.
  • Creates products for reconstructive dental procedures.

Modelo de Negocio

  • Develops and manufactures biomaterial-based medical devices.
  • Sells products directly to hospitals and clinics.
  • Distributes products through a network of distributors.
  • Generates revenue from the sale of surgical screws, binding wires, and related devices.

Contexto de la Industria

Advanced Biomedical Technologies, Inc. operates in the medical device industry, a sector characterized by rapid innovation, stringent regulatory requirements, and intense competition. The market for internal fixation devices is driven by the increasing prevalence of orthopedic trauma, sports-related injuries, and the growing demand for reconstructive dental procedures. ABMT faces competition from established medical device companies with greater resources and broader product portfolios. The company's success depends on its ability to differentiate its products, secure regulatory approvals, and effectively commercialize its technologies in a dynamic and competitive market.

Clientes Clave

  • Hospitals and surgical centers.
  • Orthopedic surgeons.
  • Dental surgeons.
  • Sports medicine clinics.
Confianza de la IA: 69% Actualizado: 16 mar 2026

Finanzas

Gráfico e información

Precio de la acción de Advanced Biomedical Technologies, Inc. (ABMT): Price data unavailable

Últimas noticias

No hay noticias recientes disponibles para ABMT.

Consenso de analistas

Calificación de Consenso

Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para ABMT.

Objetivos de Precios

Análisis del precio objetivo de Wall Street para ABMT.

MoonshotScore

68/100

¿Qué significa esta puntuación?

El MoonshotScore califica el potencial de crecimiento de ABMT en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.

Liderazgo: Hui Wang

CEO

Hui Wang is the CEO of Advanced Biomedical Technologies, Inc. His leadership is pivotal in guiding the company's strategic direction and overseeing its operations. With a team of 17 employees, Wang is responsible for driving innovation, securing funding, and navigating the regulatory landscape. His background likely includes experience in the medical device industry, with a focus on biomaterials and orthopedic applications.

Historial: As CEO, Hui Wang's track record is closely tied to the progress of Advanced Biomedical Technologies, Inc. Key milestones under his leadership include the development and commercialization of the company's polymer osteosynthesis devices. His strategic decisions have shaped the company's focus on orthopedic trauma, sports-related medical treatment, and reconstructive dental procedures. However, the company's financial performance, as indicated by its negative P/E ratio and profit margin, presents ongoing challenges.

Información del mercado OTC de ABMT

The OTC Other tier represents the lowest tier of the OTC market, indicating that Advanced Biomedical Technologies, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it difficult for investors to assess their financial health and operational performance. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ.

  • Nivel OTC: OTC Other
  • Estado de divulgación: Unknown
Liquidez: Liquidity for stocks on the OTC Other tier is typically very low, with wide bid-ask spreads and limited trading volume. This can make it difficult for investors to buy or sell shares without significantly impacting the price. The lack of liquidity increases the risk of price manipulation and makes it challenging to exit a position quickly. Investors should be prepared for potential delays in executing trades and the possibility of incurring significant transaction costs.
Factores de riesgo OTC:
  • Limited financial disclosure.
  • Low liquidity and wide bid-ask spreads.
  • Higher risk of fraud and manipulation.
  • Lack of regulatory oversight.
  • Going concern risk.
Lista de verificación de diligencia debida:
  • Verify the company's registration and legal status.
  • Review available financial statements and disclosures.
  • Assess the company's business model and competitive landscape.
  • Evaluate the management team's experience and track record.
  • Understand the risks associated with investing in OTC stocks.
  • Consult with a financial advisor.
  • Check for any regulatory actions or legal proceedings.
Señales de legitimidad:
  • Company has been in operation since 2002.
  • Focus on developing and manufacturing medical devices.
  • Products target specific medical applications.
  • Presence of a CEO and management team.
  • Company headquarters located in New York City.

Preguntas Comunes Sobre ABMT

¿Cuáles son los factores clave para evaluar ABMT?

Advanced Biomedical Technologies, Inc. (ABMT) actualmente tiene una puntuación IA de 68/100, indicando puntuación moderada. Fortaleza clave: Proprietary biomaterial technology.. Riesgo principal a monitorear: Potential: Competition from established medical device companies.. Esto no es asesoramiento financiero.

¿Qué es el MoonshotScore de ABMT?

ABMT actualmente puntúa 68/100 (Grado B) en el MoonshotScore, lo que sugiere calificación moderada. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.

¿Con qué frecuencia se actualizan los datos de ABMT?

Los precios de ABMT se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.

¿Qué dicen los analistas sobre ABMT?

La cobertura de analistas para ABMT incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.

¿Cuáles son los riesgos de invertir en ABMT?

Las categorías de riesgo para ABMT incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Competition from established medical device companies.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.

¿Cuál es la relación P/E de ABMT?

La relación P/E para ABMT compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.

¿Está ABMT sobrevalorada o infravalorada?

Determinar si Advanced Biomedical Technologies, Inc. (ABMT) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.

¿Cuál es el rendimiento por dividendo de ABMT?

Advanced Biomedical Technologies, Inc. (ABMT) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.

Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.

Recursos Oficiales

Análisis actualizado el Puntuación de IA actualizada diariamente
Fuentes de Datos y Metodología
Datos de mercado proporcionados por Financial Modeling Prep y Yahoo Finance. Análisis de IA por algoritmos propietarios de Stock Expert AI. Indicadores técnicos mediante cálculos estándar de la industria. Última actualización: .

Datos proporcionados solo con fines informativos.

Notas de análisis
  • Limited information available on OTC-listed companies.
  • Financial data may not be up-to-date.
Fuentes de datos

Popular Stocks